Armata Pharma Shares Rise 8% on FDA Breakthrough Designation for S. Aureus Drug

Armata Pharmaceuticals (NYSE American: ARMP) shares climbed 8% in trading after the company announced its product candidate, AP-SA02, received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

Regulatory Milestone

The FDA granted the designation to AP-SA02 for its use as an adjunct treatment for complicated bacteremia caused by *Staphylococcus aureus*, including both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains. According to the FDA, this designation is intended to expedite the development and review of drugs that treat a serious condition and have shown preliminary clinical evidence of substantial improvement over available therapies.

This marks the third key regulatory designation for AP-SA02, which already holds Fast Track and Qualified Infectious Disease Product (QIDP) status from the FDA. Armata is a late clinical-stage biotechnology company developing bacteriophage therapeutics to combat antibiotic-resistant infections.

Promising Clinical Data

Ad

The FDA's decision was supported by data from Armata's Phase 1b/2a diSArm study. The company reported highly favorable outcomes for patients treated with its intravenously administered multi-phage product.

Key findings from the study include:

• At a 28-day follow-up after standard antibiotic therapy, 100% of patients treated with AP-SA02 maintained a clinical response without relapse, compared to 75% of patients who received a placebo.
• The dosing regimen was well tolerated, with no serious adverse events attributed to the treatment.
• Patients receiving AP-SA02 also showed faster normalization of key biomarkers, C-reactive protein and Interleukin-10, which are associated with mortality risk in S. aureus bacteremia.